Cardamom's Metabolic and Antioxidant Effects

This is the one area where green cardamom has real randomized, placebo-controlled trials — which makes it the most interesting page in this set and also the one where the temptation to overclaim is strongest. The trials exist. They were double-blind. They had placebo arms. And they were run in two narrow, specific populations: overweight or obese adults with ultrasound-confirmed non-alcoholic fatty liver disease, and adults with type 2 diabetes. Mostly at single centres, mostly in Iran, and to a striking degree by two research groups.

That last point is where most write-ups go wrong. Search PubMed for cardamom and fatty liver and you get several papers with impressive-sounding titles. Read them and you find that a number of them report different outcomes from the same eighty-seven participants. That is entirely normal scientific practice — a well-run trial measures many things and publishes them in separate papers — but it means a result list of five papers can be one study. Counting papers instead of participants is how "cardamom is a metabolic superfood" gets written.

What follows is each trial in turn, then the meta-analysis that pooled them, then the mechanism story, then the preliminary work that is regularly quoted as though it were clinical. Everything concerns green cardamom, Elettaria cardamomum, at the recurring trial dose of 3 grams a day of powder.

Table of Contents

1. What "Metabolic" Means Here
2. The Fatty Liver Trial, in Detail
3. One Cohort, Several Papers
4. The Type 2 Diabetes Trial
5. The Meta-Analysis: Triglycerides Down, Little Else
6. Sirtuin-1, Irisin and the Mechanism Story
7. Inflammatory Markers: hs-CRP, TNF-α, IL-6
8. Antioxidant Chemistry and What It Can and Cannot Mean
9. Manganese and the Micronutrient Argument
10. Weight, BMI and the Odd Finding
11. Preliminary Work Often Quoted as Clinical
12. What a Reasonable Person Should Do With This
13. Key Research Papers
14. Connections

What "Metabolic" Means Here

"Metabolic health" in this literature means a specific set of measurable things, and it is worth naming them because cardamom did not move all of them.

• Lipids — triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol.
• Glycaemic indices — fasting plasma glucose, fasting insulin, HbA1c, and calculated insulin-resistance indices such as HOMA-IR.
• Inflammatory markers — hs-CRP, TNF-α, interleukin-6.
• Liver measures — the enzymes ALT and AST, and the ultrasound grade of hepatic steatosis.
• Anthropometry — weight, BMI, waist circumference.
• Signalling molecules — in these trials, Sirtuin-1 and irisin, which are mechanistic rather than clinical outcomes.

A crucial distinction runs through everything below. Surrogate markers are not outcomes. A lower triglyceride level, a higher Sirtuin-1 concentration or a reduced ultrasound steatosis grade are all measurements that correlate with health; none of them is the same as fewer heart attacks, less cirrhosis, or a longer life. Cardiovascular and hepatology research is full of interventions that moved surrogates convincingly and failed on outcomes. Cardamom has never been studied for a clinical outcome, and given the trial sizes involved, it could not have been.

The Fatty Liver Trial, in Detail

Evidence tier: randomized, double-blind, placebo-controlled clinical trial.

The flagship study is reported in Daneshi-Maskooni M, Keshavarz SA, Qorbani M, et al., Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial, Nutrition & Metabolism (London), 2018.

The design:

• Participants: 87 overweight or obese adults with ultrasound-confirmed non-alcoholic fatty liver disease — 43 assigned to cardamom, 44 to placebo.
• Intervention: two 500 mg green cardamom capsules three times daily — 3 grams per day.
• Control: matching placebo.
• Blinding: double-blind.
• Duration: three months.

The reported results, compared with placebo:

• Serum Sirtuin-1 increased significantly.
• hs-CRP, TNF-α and interleukin-6 all fell significantly.
• ALT fell significantly; AST did not differ significantly.
• The ultrasound-graded degree of fatty liver improved significantly.
• Weight and BMI did not differ significantly.

This is a properly designed study of respectable size, and its results are genuinely interesting. Three months of a spice powder producing a measurable change in liver enzymes and an ultrasound grade is not a trivial finding, and the drop in three separate inflammatory markers is internally consistent rather than a lone outlier.

The caveats are real and specific. It is a single trial from a single centre, and it has not been independently replicated by another group in another population. The participants were overweight or obese adults with established fatty liver in Iran — a particular population with particular diets, and the result cannot be assumed to generalise to lean people, to people without fatty liver, or to other populations. Ultrasound grading of hepatic steatosis is operator-dependent and semi-quantitative; it is the standard clinical tool, but it is coarse compared with elastography or biopsy. And the follow-up is three months, which says nothing about whether the change persists or matters over years.

One Cohort, Several Papers

This deserves its own section because it is the single most misleading feature of cardamom's search results.

The same research group published Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial in BMC Complementary and Alternative Medicine in 2019, reporting improvements in serum irisin, glucose indices and lipid profiles. There is also a published study protocol in Trials from 2017 describing the same investigation before it was run.

These are not separate trials. They are additional outcome reports and a protocol from the same 87-participant investigation. Publishing a protocol in advance is good practice — it is exactly what pre-registration is for — and splitting a rich outcome set across papers is normal. But the effect on a casual literature search is to make one study look like three or four, and that is precisely how the evidence base gets inflated in secondary writing.

Two further consequences worth understanding:

• Multiple comparisons. A trial measuring twenty outcomes across several papers will produce some significant results by chance alone. Pre-registration mitigates this by declaring the primary outcome in advance, which is one reason the protocol paper matters.
• Independent replication is the missing piece. The strength of a finding is not how many papers one group published from it — it is whether a different group, in a different population, gets the same answer. For cardamom and fatty liver, nobody has.

When you read that "multiple clinical trials show cardamom improves fatty liver," check the author lists and the sample sizes. The correct statement is: one well-designed trial of 87 people, reported across several papers.

The Type 2 Diabetes Trial

Evidence tier: randomized, double-blind, placebo-controlled clinical trial.

A separate line of work took green cardamom into type 2 diabetes. Aghasi M and colleagues published Beneficial effects of green cardamom on serum SIRT1, glycemic indices and triglyceride levels in patients with type 2 diabetes mellitus: a randomized double-blind placebo controlled clinical trial in the Journal of the Science of Food and Agriculture in 2019, with a companion protocol paper published in 2018.

The design follows the same template: adults with type 2 diabetes, green cardamom powder at the familiar 3 grams per day, a matching placebo, double blinding, and a supplementation period of a couple of months. The reported direction of effect was favourable for serum SIRT1, glycaemic indices and triglycerides.

The caveats mirror the fatty-liver work almost exactly. It is a single centre, a single trial, a modest sample, and no independent replication. The participants had established type 2 diabetes and were on their usual care, so cardamom was tested as an add-on rather than as a treatment. And critically, the meta-analysis discussed below, which pooled seven trials including this line of work, did not find a significant effect on fasting plasma glucose overall. When an individual trial and a pooled analysis disagree, the pooled analysis is usually the more reliable guide, because it is less vulnerable to a single centre's idiosyncrasies.

It is worth stating the practical implication plainly: cardamom is not a glucose-lowering treatment, and nobody with diabetes should reduce medication on the strength of this. The interesting claim is narrower — that a spice at culinary quantities may nudge triglycerides and some signalling markers as an addition to ordinary care.

The Meta-Analysis: Triglycerides Down, Little Else

Evidence tier: meta-analysis of randomized clinical trials — the highest available for cardamom.

Asbaghi O, Eslampour E, Reiner Ž, et al., Effect of green cardamom on lipoproteins, glycemic control and anthropometric parameters: a meta-analysis of randomized clinical trials, Clinical Nutrition ESPEN, 2020, pooled seven randomized trials of green cardamom. This is the closest thing to a verdict that exists.

The pooled results:

• Triglycerides fell significantly. This is the one positive lipid finding.
• No significant effect on total cholesterol.
• No significant effect on LDL cholesterol.
• No significant effect on HDL cholesterol.
• No significant effect on fasting plasma glucose.
• No significant effect on body weight.
• BMI increased significantly across three small studies. This is almost certainly statistical noise in a small pool rather than a real effect — a spice does not plausibly increase BMI while leaving weight unchanged — but it is in the published record and omitting it would be dishonest.

Two things about a seven-trial pool deserve mention. First, seven trials is a small pool by meta-analytic standards, and the individual trials were small, so confidence intervals are wide and a single study can drive a pooled result. Second, the trials came from overlapping research communities in similar populations, which limits how far the conclusion travels — a meta-analysis inherits the narrowness of its inputs.

Still, the direction is informative, and specifically the negatives are informative. The absence of an LDL effect matters, because LDL cholesterol has the strongest causal evidence for atherosclerotic disease. The absence of a fasting-glucose effect matters, because "cardamom for blood sugar" is one of the most common claims made for the spice and the pooled data does not support it.

Sirtuin-1, Irisin and the Mechanism Story

Evidence tier: measured in randomized trials, but as mechanistic markers rather than clinical outcomes.

Both trial programmes chose Sirtuin-1 as an outcome, which tells you something about the hypothesis being tested.

Sirtuin-1 (SIRT1) is an NAD⁺-dependent deacetylase involved in metabolic regulation, mitochondrial function and cellular stress responses. It is one of the proteins through which calorie restriction is thought to exert its metabolic effects, and it has been a fashionable target in nutrition research for two decades — resveratrol's reputation was built largely on claimed SIRT1 activation. Higher SIRT1 activity is broadly associated with better metabolic regulation and reduced hepatic fat accumulation in laboratory models.

Irisin is a myokine, released from muscle during exercise, which promotes browning of white adipose tissue and improved glucose handling in rodent models. Its human physiology is considerably less settled than the early literature implied, and measurement of circulating irisin has itself been contested on assay-specificity grounds.

Both are legitimate research targets and both are several steps removed from anything you would feel. An increase in serum SIRT1 concentration is not the same as increased SIRT1 activity in liver tissue, which is not the same as improved hepatic metabolism, which is not the same as less liver disease in ten years. Each of those arrows is a hypothesis. Being able to move a fashionable signalling molecule is how a supplement gets a mechanism paragraph on its label; it is not how it earns a clinical claim.

The plausible chemistry behind any real effect is unremarkable: cardamom's volatile oil (1,8-cineole, α-terpinyl acetate) has documented anti-inflammatory activity in laboratory systems, and the seed's non-volatile fraction contains modest amounts of flavonoids and phenolic acids. That is a reasonable basis for a small anti-inflammatory effect. It is not a basis for anything dramatic.

Inflammatory Markers: hs-CRP, TNF-α, IL-6

The most internally consistent result in the cardamom literature is the inflammatory one: in the fatty-liver trial, three separate inflammatory markers moved in the same direction against placebo. When several correlated markers shift together, that is more persuasive than a single isolated p-value, because chance findings tend not to line up so neatly.

What those markers mean:

• hs-CRP — high-sensitivity C-reactive protein, a liver-produced acute-phase protein and the standard clinical marker of low-grade systemic inflammation. It is also notoriously responsive to almost anything: weight change, exercise, infection, sleep, smoking, and diet composition.
• TNF-α and interleukin-6 — pro-inflammatory cytokines central to insulin resistance and to the progression of fatty liver toward inflammation and fibrosis.

Low-grade inflammation genuinely sits at the centre of metabolic disease, and reducing it is a rational target. But hs-CRP's own history is a warning: a great many interventions have lowered hs-CRP without improving any clinical outcome, and the marker's sensitivity to incidental factors means a three-month change in a modest trial should be held loosely. Reduced inflammatory markers are an encouraging signal, not a demonstrated benefit.

Antioxidant Chemistry and What It Can and Cannot Mean

Cardamom is regularly described as a potent antioxidant. Three separate things get folded into that phrase and only one of them is well established.

1. In-vitro antioxidant assays. Preliminary. Cardamom extract scavenges free radicals in test-tube assays — DPPH, FRAP, ORAC and their relatives. This is genuinely true and almost entirely uninformative, because essentially every plant extract containing phenolics does the same. These assays measure chemistry in a cuvette, at concentrations unrelated to human tissue, without any of the absorption, metabolism and distribution that determine whether a compound reaches a cell at all. A high ORAC value is a marketing number.

2. Total antioxidant status in humans. Uncontrolled human measurement. The 2009 hypertension study reported total antioxidant status rising about 90 percent over twelve weeks. That figure is quoted constantly. It comes from an uncontrolled study of twenty people, and it is a bulk plasma capacity assay — a proxy of a proxy.

3. The problem with the whole framework. This is the part usually left out. The simple "more antioxidants is better" model has been repeatedly falsified in large randomized trials. High-dose beta-carotene supplementation increased lung cancer incidence in smokers in two large trials. Vitamin E supplementation failed to reduce cardiovascular events across multiple large studies and showed signals of harm in some. And there is a well-documented reason: reactive oxygen species are not simply damage, they are signalling molecules, and exercise adaptation in particular depends on them — high-dose antioxidant supplementation has been shown to blunt some training adaptations. Indiscriminately suppressing oxidative signalling is not automatically beneficial.

None of this is a reason to avoid cardamom. It is a reason to stop treating "antioxidant" as a benefit in itself. A teaspoon of cardamom in food contributes a trivial quantity of phenolics compared with vegetables, fruit, tea, coffee, olive oil and legumes, and its antioxidant content is not a reason to take it in capsules.

Manganese and the Micronutrient Argument

Nutrition copy frequently notes that cardamom is unusually rich in manganese by weight. That is accurate and almost always misleading.

Manganese is a genuine essential trace mineral, a cofactor for manganese superoxide dismutase (the mitochondrial antioxidant enzyme), for arginase in the urea cycle, and for enzymes in bone formation. Ground cardamom's manganese density is high enough that a single teaspoon supplies a substantial fraction of the daily adequate intake.

Three reasons not to make much of it. First, manganese deficiency is essentially unknown in people eating ordinary diets — it is abundant in whole grains, nuts, legumes, leafy vegetables and tea. Solving a problem nobody has is not a benefit. Second, the amounts of cardamom used in cooking are tiny; the per-100-gram figures that make spice nutrition tables look impressive describe a quantity nobody eats. Third, excess manganese is neurotoxic — chronic overexposure, classically occupational, causes a parkinsonian syndrome, and there is no upside to pushing intake higher. If you are taking gram doses of cardamom powder plus a multivitamin plus a mineral supplement, manganese is one to glance at rather than to accumulate deliberately.

Cardamom's manganese content is a fact about its composition. It is not a reason to take it.

Weight, BMI and the Odd Finding

Cardamom appears in weight-loss content, and the trial data is unambiguous in the other direction.

The fatty-liver trial found no significant difference in weight or BMI between cardamom and placebo over three months. The meta-analysis of seven trials found no significant effect on body weight, and reported a significant increase in BMI across three small studies — a result that is internally incoherent (weight unchanged, BMI up, in adults whose height does not change) and is best read as noise in a small, heterogeneous pool. Either way, nothing in the human record supports cardamom as a weight-loss agent.

The rodent literature is where the claim originates: animal studies of cardamom and related Zingiberaceae have reported effects on body fat and metabolic parameters in high-fat-fed rodents. Rodent obesity models routinely produce metabolic effects that fail to replicate in humans, at doses that scale to implausible human intakes. Preliminary at best, and contradicted by the human data.

The one honest connection between cardamom and body weight is indirect: strongly flavoured food is satisfying, and spices let you make food interesting without sugar, without excess salt and without relying on fat for flavour. That is a real advantage of cooking with spice. It is not pharmacology.

Preliminary Work Often Quoted as Clinical

Three bodies of preliminary research get cited on cardamom pages as though they were results in people. Each is legitimate laboratory science and none supports a human claim.

Cancer cell lines and rodent tumour models. Preliminary. Cardamom extracts and their constituent compounds inhibit proliferation and induce apoptosis in various cultured cancer cell lines, and rodent work has examined cardamom in chemically induced carcinogenesis, including liver and skin models. This is a very large and very low-yield genre: the overwhelming majority of compounds that kill cancer cells in a dish do nothing useful in a person, because a dish has no pharmacokinetics, no immune system and no dose-limiting toxicity. Separately, note that the frequently cited apoptosis work on lung cancer cells used black cardamom (Amomum subulatum) — a different genus entirely. Cardamom is not a cancer treatment and there are no human cancer trials.

Anti-inflammatory and antioxidant rodent studies. Preliminary. Cardamom reduces inflammatory markers and oxidative-stress measures in rodent tissue in several reports. Consistent with the human inflammatory findings, and at concentrations and durations chosen by the experimenter.

1,8-cineole's own clinical literature. This one is the most seductive because the trials are real. Purified cineole has been through placebo-controlled human trials in respiratory conditions and is a licensed medicine in parts of Europe. It is one of cardamom's two dominant volatiles. And it is still not cardamom evidence — it is evidence about an isolated compound administered at a defined therapeutic dose in a controlled formulation. Reasoning from a purified drug back to the plant it can be found in is the most common error in supplement writing, and it is worth refusing every time.

What a Reasonable Person Should Do With This

The defensible summary, stated as narrowly as the data allows:

Green cardamom at approximately 3 grams per day may modestly lower triglycerides and some inflammatory markers, and may modestly improve liver enzymes and ultrasound-graded steatosis in overweight or obese adults with non-alcoholic fatty liver disease, based on a small number of trials largely from single centres and without independent replication. It does not appear to change total, LDL or HDL cholesterol, fasting glucose or body weight.

Practically:

• Cook with it freely. It is a good spice, it costs you nothing in risk, and it lets you flavour food without sugar or excess salt.
• If you want the trial exposure, that is 3 grams a day of green cardamom powder in two or three divided doses with meals — roughly a heaped teaspoon, or the seeds from twenty-five to thirty pods. It is safe and it is cheap. Expect a modest triglyceride nudge at most, and nothing you will feel.
• Do not substitute it for treatment. Fatty liver disease responds to weight reduction, reduced alcohol, treating diabetes and increasing physical activity — interventions with far larger effects than anything on this page. Type 2 diabetes needs its medication and its monitoring. Raised triglycerides respond most to alcohol reduction, carbohydrate quality, weight and glycaemic control.
• Do not buy expensive cardamom extract. Every trial used ordinary green cardamom powder. There is no evidence for standardised extracts, and concentrating the active fraction is exactly what turns the safety profile from "spice" into "unknown."
• Watch the interactions. If you take an anticoagulant or antiplatelet drug, stay at culinary amounts — see the blood-pressure page for the fibrinolysis finding. Cardamom constituents modulate several cytochrome P450 enzymes in laboratory systems, which is not a concern in cooking but is a reason not to take concentrated extracts casually alongside a long medication list.
• If you have fatty liver or diabetes and want to try it, tell your doctor, keep taking your prescribed treatment, and let your routine blood tests answer the question for your own body. Liver enzymes and a lipid panel are cheap and already being measured.

Key Research Papers

Each citation is given as a PubMed search with the paper's title, journal and year stated, so you can confirm you have the right record. Search links cannot resolve to the wrong paper.

1. Daneshi-Maskooni M, Keshavarz SA, Qorbani M, et al. Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial. Nutrition & Metabolism (London), 2018. 87 adults, 3 g/day, three months. Find on PubMed — randomized clinical trial.
2. Daneshi-Maskooni M, Keshavarz SA, Qorbani M, et al. Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial. BMC Complementary and Alternative Medicine, 2019. Same cohort, further outcomes. Find on PubMed — randomized clinical trial, same cohort.
3. Daneshi-Maskooni M, Keshavarz SA, Mansouri S, et al. The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease: study protocol for a randomized controlled trial. Trials, 2017. The pre-registered protocol for the above. Find on PubMed — protocol.
4. Aghasi M, et al. Beneficial effects of green cardamom on serum SIRT1, glycemic indices and triglyceride levels in patients with type 2 diabetes mellitus: a randomized double-blind placebo controlled clinical trial. Journal of the Science of Food and Agriculture, 2019. Find on PubMed — randomized clinical trial.
5. Asbaghi O, Eslampour E, Reiner Ž, et al. Effect of green cardamom on lipoproteins, glycemic control and anthropometric parameters: a meta-analysis of randomized clinical trials. Clinical Nutrition ESPEN, 2020. Seven pooled trials. Find on PubMed — meta-analysis of randomized trials.
6. Ashokkumar K, Murugan M, Dhanya MK, Warkentin TD. Botany, traditional uses, phytochemistry and biological activities of cardamom [Elettaria cardamomum (L.) Maton] — a critical review. Journal of Ethnopharmacology, 2020. Find on PubMed — review.
7. Verma SK, Jain V, Katewa SS. Blood pressure lowering, fibrinolysis enhancing and antioxidant activities of cardamom (Elettaria cardamomum). Indian Journal of Biochemistry and Biophysics, 2009. Source of the widely quoted antioxidant-status figure, and of the fibrinolysis caution. Find on PubMed — uncontrolled human pilot study.
8. Cardamom and non-alcoholic fatty liver disease — the complete set of publications from this line of work; useful for seeing the cohort reuse yourself.
9. Green cardamom in type 2 diabetes, randomized trials.
10. SIRT1, metabolic regulation and hepatic steatosis — the mechanism the trials were built around.
11. Irisin, its human physiology and assay controversies — why the irisin result should be held loosely.
12. Beta-carotene supplementation and lung cancer in smokers — the clearest evidence that "more antioxidant" is not automatically better.
13. Antioxidant supplementation and exercise training adaptation — reactive oxygen species as signalling molecules, not just damage.
14. Manganese excess and neurotoxicity — the other side of the manganese-rich claim.
15. Weight reduction and lifestyle intervention in fatty liver disease — the intervention with a far larger effect than any spice.

Safety and Disclaimer

Green cardamom was well tolerated at 3 grams a day for up to three months in the trials described here, with no significant adverse effects reported, and culinary use is safe for almost everyone. It is not a treatment for fatty liver disease, type 2 diabetes, high cholesterol or obesity, and it must not replace prescribed medication or medical monitoring. The findings above are surrogate markers in small, largely unreplicated trials in two specific populations, and they do not generalise to everyone. If you take warfarin, a direct oral anticoagulant, clopidogrel or high-dose aspirin, keep cardamom to food amounts because of the reported increase in fibrinolytic activity. Keep to culinary amounts if you have known gallstones or are pregnant, and stop concentrated supplements about two weeks before surgery. Avoid stacking gram doses of cardamom powder with multiple mineral supplements given its manganese density. This page is educational and is not medical advice; discuss any gram-level supplement with your doctor or pharmacist if you take prescription medication.

Connections

• All Herbs
• Cardamom (Elettaria cardamomum) — the main topic page: botany, green versus black, dosage, cautions.
• Cardamom — Benefits Deep Dive — the hub for all four benefit articles.
• Cardamom for Blood Pressure and Heart Health — including the fibrinolysis interaction referenced above.
• Non-Alcoholic Fatty Liver Disease — the population in cardamom's best-designed trial.
• Type 2 Diabetes — the other trial population.
• Insulin Resistance — the process linking inflammation to metabolic disease.
• Metabolic Syndrome — the cluster these markers belong to.
• Obesity — where the real weight interventions live.
• Lipid Panel — where a triglyceride change would show up.
• hs-CRP — the inflammatory marker the fatty-liver trial moved.
• Liver Function Tests — ALT and AST, the enzymes measured in that trial.
• Manganese — the mineral cardamom is unusually rich in, and its upper limits.
• Antioxidants — the wider framework, including where it breaks down.
• Resveratrol — the other compound whose reputation was built on SIRT1.
• Curcumin — a Zingiberaceae relative's compound with the same surrogate-marker problem at larger scale.
• Cinnamon — Benefits — the other warm spice with a glucose literature and replication trouble.
• Fenugreek — a spice with a somewhat stronger glycaemic trial record.
• Berberine — the plant compound with genuinely substantial metabolic trial data, for comparison.
• Milk Thistle — the traditional liver herb, with its own mixed evidence.

Back to Table of Contents